title: Leishmaniasis.
abstract: Leishmaniasis is a disease that ranges in severity from skin lesions to serious disfigurement and fatal systemic infection. WHO has classified the disease as emerging and uncontrolled and estimates that the infection results in two million new cases a year. There are 12 million people currently infected worldwide, and leishmaniasis threatens 350 million people in 88 countries. Vaccination remains the best hope for control of all forms of the disease, and the development of a safe, effective and affordable antileishmanial vaccine is a critical global public-health priority. However, to date, no such vaccine is available despite substantial efforts by many laboratories. Main obstacle in vaccine design is the transition from the laboratory to the field and extrapolation of data from animal models to humans. This review discusses recent findings in the antileishmania vaccine field and current difficulties hampering vaccine implementation.
authors: Inflammation Division, Walter+Eliza Hall Institute of Medical Research, Department of Medical Biology, The University of Melbourne, Parkville, Australia. kedzierski@wehi.edu.au
authors: Lukasz
authors: L
authors: Kedzierski
mesh_terms: D000818:Animals; D004285:Dogs; D006801:Humans; D007891:Leishmania / Q000276:immunology*; D016773:Leishmaniasis, Cutaneous / Q000276:immunology / Q000517:prevention & control*; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D015800:Protozoan Proteins / Q000235:genetics / Q000276:immunology; D016052:Protozoan Vaccines / Q000235:genetics / Q000276:immunology*; D014611:Vaccination; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology*
chemical_list: D015800:Protozoan Proteins; D016052:Protozoan Vaccines; D019444:Vaccines, DNA